@article{Kelly_E-2023_142316,
title = {Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A Randomised Controlled Trial},
author = {Kelly, E. and Greenland, M. and de Whalley, P. and Aley, P. and Plested, E. and Singh, N. and Koleva, S. and Tonner, S. and Macaulay, G. and Read, R. and Ramsay, M. and Cameron, J. and Turner, D. and Heath, P. and Bernatoniene, J. and Connor, P. and Cathie, K. and Faust, S. and Banerjee, I. and Cantrell, L. and Mujadidi, Y. and Belhadef, H. and Clutterbuck, E. and Anslow, R. and Valliji, Z. and James, T. and Hallis, B. and Otter, A. and Lambe, T. and Nguyen-Van-Tam, J. and Minassian, A. and Liu, X. and Snape, M. and COM-COV3 Study Group},
month = {jun},
year = {2023},
abstract = {BackgroundThis was the first study to investigate the reactogenicity andimmunogenicityof heterologous or fractional second dose COVID-19 vaccine regimens in adolescents.},
journal = {Journal of Infection},
publisher = {Elsevier},
url = {https://doi.org/10.1016/j.jinf.2023.06.007},
}
